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The underlying cause for the failure of immune check-
point blockade is the overwhelming, persistent and multifo-
cal immune suppression in the tumor microenvironment.
This is due to the absence of pre-existing antitumor Teff
because of the action of important upstream immune
checkpoints that recruit immunosuppressive cytokines (e.g.,
TGF-beta and IL-10) and tumor infiltrating myeloid-
derived suppressor cells (MDSCs), regulatory T cells
(Tregs) and M2 macrophages that can occupy up to 50% of
the tumor mass.
The membrane phospholipid, phosphatidylserine (PS), is
an upstream immune checkpoint. In normal non-tumori-
genic cells, PS is segregated to the inner leaflet of the
plasma membrane but becomes externalized to the outer
leaflet of the plasma membrane in cells in the tumor
microenvironment. PS is recognized and bound by PS
receptors on immune cells where it induces and maintains
immune suppression. PS-targeting agents block PS-
mediated immunosuppression by multifocal reprograming
of the immune cells in the tumor microenvironment to
support immune activation. Antibody-mediated PS block-
ade reduces the levels of MDSC, TGF-beta, and IL-10 and
increases the levels of TNF-alpha and IL-12. PS blockade
also re-polarizes tumor-associated macrophages (TAM’s)
from predominant M2 to predominant M1 phenotype,
promotes the maturation of dendritic cells (DC’s) and
induces potent adaptive antitumor T cell immunity.
In a Phase II clinical study, immunohistochemical eva-
luation of HCC tumor tissues post combination treat-
ment indicated an increase of immune infiltrates; raising
the potential of a clinically meaningful anti-tumor
immune response. Pre-clinically, we demonstrate that
PS targeting agents enhance the anti-tumor activity of
anti-CTLA-4 and anti-PD-1 antibodies in immunocom-
petent models of melanoma (B16 and K1735) and breast
(EMT-6) cancer and that tumor growth inhibition corre-
lates with an increase in the infiltration of activated
T cells and myeloid cells and the induction of adaptive
immunity. In summary, PS blockade in combination
with targeted therapy and other immune checkpoint
inhibitors promotes a robust, localized, anti-tumor
response and represents a promising strategy to enhance
cancer immunotherapy.
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